Altimmune, Inc. ALT R2K

Healthcare · Biotechnology · United States

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Market & Price

Market Cap

$593.15M

Current Price

$3.05

High / Low (52W)

$7.71 / $2.60

Beta

0.17

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

32.62

Book Value

$2.18

Price to Book

1.40

P/S

16,476.28

EV/EBITDA

-3.10

Dividend Yield

Profitability & Returns

ROCE

-32.89%

ROE

-42.75%

ROA

-24.40%

Profit Margin

0.00%

Op Margin

EPS (Latest Qtr)

$-0.18

EPS (TTM)

$-0.92

Balance Sheet & Liquidity

Debt/Equity

0.13

Quick Ratio

29.43

Current Ratio

29.56

Debt

$35.85M

Total Assets

$279.93M

Current Assets

$278.19M

Working Capital

$263.19M

Ownership

Promoter Holding

0.40%

Chg in Prom Hold

-0.01%

FII / Inst Holding

57.82%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

$297.45M

Total Revenue (TTM)

$36.00K

EBITDA

$-96.10M

Free Cash Flow

$-42.50M

Operating Cash Flow

$-71.64M

Shares Outstanding

194.47M

Gross Margin

0.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

53.43%

Profit 5Y

-1.33%

Revenue (YoY)

Earnings (YoY)

PROS

Compounding revenue at 53.4% over 5 years.

CONS

Earnings shrank at -1.3% CAGR over 5 years.
Trading 60.4% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ALT Altimmune, Inc. R2K	3.05	-	$593.15M	-	-32.89%	-42.75%	53.43%	-1.33%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2014	Sep 2014	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	3.04M	4.59M	2.69M	2.42M	2.63M	2.96M	1.63M	643.98K	2.21M	721.64K	2.94M	838.00K	137.00K	158.00K	32.00K	8.00K	2.00K	-	-	-	-	-	-	5.00K	5.00K	5.00K	26.00K	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21.82M	22.93M	20.86M	28.92M	24.24M
Operating Income	-1.17M	-4.00M	-2.62M	1.16M	-1.96M	-1.66M	-940.47K	-1.25M	-1.60M	-4.79M	-5.51M	-4.52M	-4.01M	-30.95M	-5.99M	-5.44M	-4.06M	-2.33M	-3.55M	-11.27M	-7.31M	-18.42M	-18.32M	-14.86M	-24.86M	-33.20M	-19.50M	-20.39M	-24.75M	-21.76M	-18.01M	-22.54M	-26.79M	-26.75M	-24.77M	-21.82M	-22.92M	-20.86M	-28.89M	-24.24M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-20.23M	-21.85M	-18.49M	-26.46M	-21.47M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00K	264.00K	495.00K	876.00K	1.07M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-20.26M	-22.15M	-19.01M	-27.36M	-22.56M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-681.00K	0	0	0	0
Net Income	-439.12K	-4.63M	-2.63M	1.46M	-2.34M	-1.32M	-1.24M	-1.23M	-1.62M	-4.80M	77.80M	-4.58M	-3.11M	-29.91M	-3.17M	-9.14M	-2.35M	-2.10M	-3.39M	-10.94M	-3.89M	-16.77M	-17.77M	-14.86M	-24.83M	-33.51M	-19.43M	-20.11M	-23.52M	-20.07M	-16.06M	-20.67M	-24.39M	-24.64M	-22.84M	-19.57M	-22.15M	-19.01M	-27.36M	-22.56M
Diluted EPS	-0.01	-0.08	-0.04	0.02	-0.04	-0.02	-0.02	-0.02	0.12	1.67	1.15	-	-	-	-	-	-	-	-	-	-	-	-0.54	-0.38	-0.60	-0.81	-0.44	-0.42	-0.48	-0.40	-0.32	-0.39	-0.34	-0.35	-0.32	-0.26	-0.27	-0.21	-0.27	-0.18
R&D Expense	2.37M	1.73M	-	1.61M	1.22M	1.13M	-	1.03M	1.38M	2.40M	-	2.79M	5.25M	5.91M	5.75M	4.92M	4.73M	3.22M	2.95M	8.73M	7.19M	16.59M	17.04M	11.88M	13.27M	29.21M	15.10M	15.99M	20.26M	17.25M	13.25M	18.39M	21.49M	21.16M	19.80M	15.83M	17.24M	14.96M	-	16.19M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	10.74M	10.33M	5.80M	8.19M	-	-68.00K	426.00K	20.00K	41.00K
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	87.67M	83.94M	103.19M	94.53M
Operating Income	-23.55M	-11.73M	-6.27M	-10.84M	-10.19M	-3.40M	-11.09M	-52.05M	-42.83M	-21.46M	-54.80M	-	-87.74M	-83.51M	-103.17M	-94.49M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-84.41M	-87.94M	-94.81M	-87.03M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	8.00K	35.00K	9.00K	1.64M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-84.91M	-88.45M	-95.06M	-88.77M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-197.00K	0	0	-681.00K
Net Income	-34.85M	-3.80M	-4.92M	-11.72M	-9.96M	-3.44M	-11.09M	-46.43M	-39.17M	-20.52M	-49.04M	-	-84.71M	-88.45M	-95.06M	-88.09M
Diluted EPS	-	-	-	-	-0.17	-0.05	2.95	-	-	-	-1.91	-	-1.81	-1.66	-1.34	-1.00
R&D Expense	20.88M	21.22M	19.51M	15.29M	9.32M	5.13M	7.22M	18.41M	18.46M	17.77M	49.77M	74.54M	70.54M	65.80M	82.23M	66.43M

Compounded Sales Growth

5 Years:	53.43%
1 Year:	-

Compounded Profit Growth

5 Years:	-1.33%
1 Year:	-

Stock Price Performance

1 Year:	-43.83%
6 Months:	-40.66%
3 Months:	-29.23%
1 Month:	+15.97%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	27.20M	22.80M	22.74M	17.14M	21.98M	19.86M	38.40M	63.03M	54.75M	54.06M	245.12M	-	206.93M	210.64M	139.31M	279.93M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	192.81M	209.63M	137.25M	278.19M
Cash & Equivalents	2.67M	11.79M	11.24M	12.70M	10.48M	18.64M	15.57M	2.88M	8.77M	33.72M	8.96M	115.92M	-	111.10M	135.12M	36.93M	43.76M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	173.00K	1.11M	544.00K	1.22M
Total Liabilities	-	14.99M	6.95M	11.07M	9.80M	3.70M	3.21M	6.19M	14.35M	6.44M	8.54M	19.24M	-	21.64M	16.54M	15.80M	55.04M
Current Liabilities	-	6.16M	4.62M	7.49M	6.80M	2.58M	2.18M	5.47M	3.84M	4.53M	3.92M	12.02M	-	17.05M	12.14M	10.47M	15.00M
Long Term Debt	-	-	-	1.70M	730.28K	-	-	-	-	1.85M	1.86M	1.83M	-	-	-	-	34.29M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	1.12M	671.00K	1.68M	35.69M
Total Equity	3.15M	12.21M	15.85M	11.67M	7.34M	18.27M	43.13M	32.21M	39.40M	48.31M	45.52M	225.88M	-	185.29M	194.10M	123.51M	224.89M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	49.20M	70.68M	72.35M	110.88M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-14.86M	-7.81M	-2.32M	-	-	-	-	-20.21M	-9.39M	-9.60M	-34.31M	-	-62.59M	-75.81M	-79.85M	-67.53M
Investing Cash Flow	2.76M	1.69M	67.40K	-	-	-	-	13.73M	-1.00M	-28.29M	-72.23M	-	-73.40M	13.73M	-28.39M	-132.47M
Financing Cash Flow	21.46M	5.78M	3.72M	-	-	-	-	15.84M	32.49M	12.53M	213.49M	-	56.78M	86.11M	10.04M	206.84M
Capital Expenditure	-374.58K	-71.44K	-	-84.58K	-92.27K	-86.51K	-124.95K	-112.44K	-975.41K	-1.23K	-203.96K	-12.31M	-126.00K	-47.00K	-	-11.00K
Free Cash Flow	-15.24M	-7.88M	-	-	-	-	-	-20.33M	-10.36M	-9.60M	-34.51M	-	-62.71M	-75.86M	-79.85M	-67.55M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-79.20M	24.03M	-98.19M	6.83M

Ratios (Annual)

Figures in %.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	-484.7%	-414.6%	-370.0%	-669.5%	-	129,029.4%	-19,603.3%	-515,860.0%	-230,461.0%
Net Margin %	-	-	-	-	-	-	-	-432.3%	-379.2%	-353.7%	-599.2%	-	124,577.9%	-20,762.2%	-475,295.0%	-214,861.0%
ROE %	-285.4%	-24.0%	-42.1%	-159.7%	-54.5%	-8.0%	-34.4%	-117.8%	-81.1%	-45.1%	-21.7%	-	-45.7%	-45.6%	-77.0%	-39.2%
ROCE %	-112.0%	-64.5%	-41.1%	-104.8%	-52.5%	-19.2%	-33.7%	-87.9%	-85.3%	-42.8%	-23.5%	-	-46.2%	-42.1%	-80.1%	-35.7%

Shareholding Pattern

Insiders

0.40%

Institutions

57.82%

Public Float

58.06%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	6.58%	12.80M	$39.03M
2	State Street Corporation	3.67%	7.15M	$21.79M
3	Vanguard Capital Management LLC	2.91%	5.66M	$17.26M
4	Vanguard Portfolio Management LLC	2.77%	5.38M	$16.42M
5	Marshall Wace LLP	2.07%	4.02M	$12.25M
6	Millennium Management Llc	1.68%	3.26M	$9.94M
7	Geode Capital Management, LLC	1.60%	3.11M	$9.48M
8	Alyeska Investment Group, L.p.	1.36%	2.64M	$8.07M
9	Two Sigma Investments, LP	1.27%	2.48M	$7.56M
10	Nuveen, LLC	1.20%	2.33M	$7.12M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ALT

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Sector	Healthcare
Industry	Biotechnology
Headquarters	United States
Employees	57
Website	https://altimmune.com

Altimmune, Inc. ALT R2K

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More